163 related articles for article (PubMed ID: 30595153)
1. [Not Available].
Borchiellini D
Bull Cancer; 2018 Dec; 105 Suppl 3():S242-S254. PubMed ID: 30595153
[TBL] [Abstract][Full Text] [Related]
2. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
Swallow E; Messali A; Ghate S; McDonald E; Duchesneau E; Perez JR
J Manag Care Spec Pharm; 2018 Apr; 24(4):335-343. PubMed ID: 29578848
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy in metastatic renal cell carcinoma.
Bedke J; Gauler T; Grünwald V; Hegele A; Herrmann E; Hinz S; Janssen J; Schmitz S; Schostak M; Tesch H; Zastrow S; Miller K
World J Urol; 2017 Feb; 35(2):179-188. PubMed ID: 27277600
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis.
Manz KM; Fenchel K; Eilers A; Morgan J; Wittling K; Dempke WCM
Adv Ther; 2020 Feb; 37(2):730-744. PubMed ID: 31838709
[TBL] [Abstract][Full Text] [Related]
5. Network meta-analysis of second line and beyond treatment options in metastatic clear cell renal cell carcinoma.
Obeng-Kusi M; Kreutzfeldt JJ; Estrada-Mendizabal RJ; Choi BM; Abraham I; Recio-Boiles A
Urol Oncol; 2024 Feb; 42(2):32.e1-32.e8. PubMed ID: 38216444
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan.
Chandler C; Burnett H; Schaible K; Senthil V; Kato M; Miura Y; Osawa T; Uemura H; Kuwabara H
J Med Econ; 2023; 26(1):1009-1018. PubMed ID: 37505931
[TBL] [Abstract][Full Text] [Related]
7. Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis.
She X; Yin D; Guo Q; Tang Y; Wang S; Wang X
Sci Rep; 2024 Mar; 14(1):5592. PubMed ID: 38454105
[TBL] [Abstract][Full Text] [Related]
8. BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials.
Liu K; Huang Y; Xu Y; Wang G; Cai S; Zhang X; Shi T
Cancer Immunol Immunother; 2023 Aug; 72(8):2557-2572. PubMed ID: 37046008
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma.
Henriksen JN; Andersen CU; Fristrup N
Clin Genitourin Cancer; 2024 Jun; 22(3):102064. PubMed ID: 38555681
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib for the treatment of renal cell carcinoma.
Welsh SJ; Fife K
Future Oncol; 2015; 11(8):1169-79. PubMed ID: 25832874
[TBL] [Abstract][Full Text] [Related]
11. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy.
Zarrabi K; Fang C; Wu S
J Hematol Oncol; 2017 Feb; 10(1):38. PubMed ID: 28153029
[TBL] [Abstract][Full Text] [Related]
12. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
Cella D; Escudier B; Tannir NM; Powles T; Donskov F; Peltola K; Schmidinger M; Heng DYC; Mainwaring PN; Hammers HJ; Lee JL; Roth BJ; Marteau F; Williams P; Baer J; Mangeshkar M; Scheffold C; Hutson TE; Pal S; Motzer RJ; Choueiri TK
J Clin Oncol; 2018 Mar; 36(8):757-764. PubMed ID: 29377755
[TBL] [Abstract][Full Text] [Related]
13. SEOM SOGUG clinical guideline for treatment of kidney cancer (2022).
Méndez-Vidal MJ; Lázaro Quintela M; Lainez-Milagro N; Perez-Valderrama B; Suárez Rodriguez C; Arranz Arija JÁ; Peláez Fernández I; Gallardo Díaz E; Lambea Sorrosal J; González-Del-Alba A
Clin Transl Oncol; 2023 Sep; 25(9):2732-2748. PubMed ID: 37556095
[TBL] [Abstract][Full Text] [Related]
14. A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region.
So TH; Sharma S; Parij R; Spiteri C; Chawla E; Pandey P; Rajasekaran T
Expert Rev Anticancer Ther; 2023; 23(8):853-863. PubMed ID: 37458169
[TBL] [Abstract][Full Text] [Related]
15. The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers.
Starzer AM; Wolff L; Popov P; Kiesewetter B; Preusser M; Berghoff AS
Cancer Treat Rev; 2024 Apr; 125():102718. PubMed ID: 38521009
[TBL] [Abstract][Full Text] [Related]
16. Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review.
Smaletz O
Int Braz J Urol; 2015; 41(5):835-43. PubMed ID: 26689508
[TBL] [Abstract][Full Text] [Related]
17. PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors.
Stokes ME; Calvo V; Fujisawa S; Dudgeon C; Huang S; Ballal N; Shen L; Gasparek J; Betzenhauser M; Taylor SJ; Staschke KA; Rigby AC; Mulvihill MJ; Bose N; Lightcap ES; Surguladze D
Clin Cancer Res; 2023 Dec; 29(23):4870-4882. PubMed ID: 37733811
[TBL] [Abstract][Full Text] [Related]
18. Re: Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, et al. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023;6:339-348.
Chadha J; Chahoud J
Eur Urol Oncol; 2024 Feb; 7(1):172. PubMed ID: 37357090
[No Abstract] [Full Text] [Related]
19. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Doehn C; Gschwend JE; Kuczyk MA
Aktuelle Urol; 2019 Sep; ():. PubMed ID: 31486061
[TBL] [Abstract][Full Text] [Related]
20. Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy.
Drobner J; Portal D; Runcie K; Yang Y; Singer EA
J Kidney Cancer VHL; 2023; 10(3):37-60. PubMed ID: 37789902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]